Document:

Summary Sheet of Director Fees and Exectutive Officer Compensation

 EXHIBIT 10.13 
 SUMMARY SHEET OF DIRECTOR FEES AND EXECUTIVE OFFICER COMPENSATION 
 I.    Director Compensation 
 As
compensation for their service as directors of The Providence Service Corporation (the “Company”), each non-employee member of the Board of Directors (the “Board”) receives a $10,000 annual stipend, except for the Audit Committee
Chair who receives a $28,800 annual stipend. Payment of the annual stipends is made on a quarterly basis following each quarter of service. Additionally, each non-employee member of the Board receives $3,500 for each Board meeting attended in
person, $1,000 for each telephonic meeting of the Board participated in, and $1,000 for each committee meeting attended or participated in by telephone of which such non-employee member of the Board is a member that is not held the same day as a
Board meeting, except that the Audit Committee Chair receives $2,500 for each Audit Committee meeting attended or participated in by telephone that is not held the same day as a Board meeting. 
 In addition, each non-employee member then serving on the first business day of each January receives a ten year option to purchase 10,000 shares of the
Company’s common stock under the Company’s 2003 Stock Option Plan with an exercise price equal to the closing market price of the Company’s common stock on the date of grant. For services to be rendered in 2006, each non-employee
director was awarded an option to purchase 10,000 shares of the Company’s common stock on December 6, 2005 under the Company’s 2003 Stock Option Plan in lieu of receiving the award in January 2006. On December 29, 2005, the
vesting of all unvested options then outstanding, including those options awarded to non-employee directors, were accelerated. 
 II.    Executive Compensation 
 Base Salaries 
 The following table sets forth current base salaries of the Company’s CEO and each of the executive officers who were named in the Summary
Compensation Table in the Company’s definitive proxy statement filed with the SEC on April 20, 2005 and each executive officer expected to be named in the Summary Compensation Table in the Company’s definitive proxy statement to be
filed with the SEC with respect to the Company’s 2006 annual stockholders meeting (the “Named Executive Officers”). 
  

				
	 Name
	  	Base Salary
	 Fletcher Jay McCusker
	  	$	250,000
	 William Boyd Dover
	  	 	190,000
	 Michael N. Deitch
	  	 	195,000
	 Fred D. Furman
	  	 	195,000
	 Craig A. Norris
	  	 	200,000

 Bonuses 
 Annual Incentive Compensation Plan 
 Each Named Executive Officer is eligible to receive a bonus under
the Annual Incentive Compensation Plan. The Annual Incentive Compensation Plan is designed as a team bonus and is not triggered unless the Company meets or exceeds its budgeted net income and earnings per share for fiscal 2006 (calculated after
giving effect to any bonuses accrued under the Annual Incentive Compensation Plan and the Quarterly Incentive Bonus Plan). Individuals of the bonus team are eligible to receive a cash bonus as follows: (1) if net income and earnings per share
exceeds budgeted target amounts by 1% to 5%, the cash bonus payable to each individual will be 25% of the individual’s 2006 base salary; and (2) if net income and earnings per share exceeds budgeted target amounts by more than 5%, the cash
bonus payable to each individual will be 50% of the individual’s 2006 base salary. 

 Quarterly Incentive Bonus Plan 
 Each Named Executive Officer is eligible to receive a bonus under the Quarterly Incentive Bonus Plan. The Quarterly Incentive Bonus Plan is designed as a
team bonus and is triggered if the Company meets or exceeds its budgeted net income and earnings per share for each quarter during the Company’s fiscal year (calculated after giving effect to any bonuses accrued under the Quarterly Incentive
Bonus Plan and the Annual Incentive Compensation Plan). Individuals of the bonus team are eligible to receive a cash bonus of $5,000 for each quarter the bonus is triggered under the Quarterly Incentive Bonus Plan. The total annual amount each
individual of the bonus team may receive under the Quarterly Incentive Bonus Plan is $20,000. 
 Participation in Stock Option Plan and Other Arrangements

 The Named Executive Officers are also eligible to: 
  

	 	•	 	Participate in the Company’s 2003 Stock Option Plan; 

  

	 	•	 	Participate in certain group life, health, medical and other non-cash benefits generally available to all salaried employees; and 

  

	 	•	 	Participate in certain health and dental benefits for their family, which are not available to all salaried employees.License Agreement, as amended, dated March 14, 2006 - Chugai Phamaceuticals

 Exhibit 10.26 
 

 
  

					
	

	  	 101 Convention Center Drive, Suite 850
 Las Vegas, NV
89109
	  	 T 702.380.5897
 F
702.598.3651

 VIA FACSIMILE (+81-3-3281-6610) 
 AND FEDERAL EXPRESS 
 March 9, 2006 
 Mr. Kimio Nishimura 
 General Manager 
 Business Development Department 
 Chugai Pharmaceutical Co., Ltd. 

1-1, Nihonbashi-Muromachi 2-chome, 
 Chuo-ku, Tokyo 103-8324 
 Japan 
  

	Re:	License Agreement dated October 19, 2001 as amended / Xyotax 

 CONFIDENTIAL – SUBJECT TO F.R.E. 408 
 Dear Mr. Nishimura: 
 This letter agreement sets forth the agreement between Chugai Pharmaceutical Co., Ltd. (“Chugai”) and CTI Technologies, Inc. (“CTIT”) to terminate, as
of the date hereof, the License Agreement, dated October 19, 2001 (as amended) (the “License Agreement”) between Chugai and CTIT. 
 Chugai and CTIT hereby agree that the License Agreement is terminated as of the date hereof. 
 Promptly following the date
hereof, Chugai will return to CTIT, as soon as practicable, all Xyotax data, documents, and materials (the “Xyotax Materials”), including but not limited to vendor audit reports (raw material, API, finished product); manufacturing reports
and documents (including any formulation work); preclinical reports and data; patent information and reports; clinical data sets (SAS data sets and clinical trial reports for all studies); marketing materials and plans; regulatory documents and
correspondence (FDA, EMEA, Japanese Ministry of Health minutes, submissions); and any other confidential documents related to Xyotax (from teleconferences, meetings, emails). 
 As reimbursement for administrative expenses incurred by CTIT in connection with this termination, Chugai will remit to CTIT by wire transfer US Dollar Ten Thousand ($10,000) no later than fourteen (14) business
days after Chugai’s receipt of this letter agreement signed by CTIT. 
 Subject to compliance with the above, each of Chugai and CTIT agrees, for itself
and its Affiliates (including without limitation Cell Therapeutics, Inc.), that it absolutely, irrevocably, 

 Page 2 
 March 9, 2006 
 Chugai Pharmaceutical Co., Ltd. 
 fully and forever releases the other party and its Affiliates, parent, subsidiaries, agents, representatives,
officers, directors, employees, shareholders, partners, members, successors and assigns from any and all claims, demands, liabilities, obligations, promises, causes of action, suits, judgments, taxes, liens, losses, fines, costs, expenses,
royalties, litigation, deficiencies or damages (including reasonable attorneys’ fees and expenses) of whatever kind or nature, in law or in equity, known or unknown, which it, its Affiliates, successors or assigns now or hereafter have or may
have against the other party, or any of them, arising out of the License Agreement, including without limitation any prior use of the Xyotax Materials. For purposes of this letter, “Affiliates” shall mean as to any person or entity, any
other person or entity that directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, the first person or entity, and “control” (including the terms “controlled by”
and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of a person or entity, whether through the ownership of voting securities, by contract
or credit agreement, as trustee or executor, or otherwise. 
 The parties hereby further agree that neither party has any further obligations of any kind to
the other party arising out of the License Agreement, except as specifically set forth in Section 10.4.2 therein. 
 The parties hereby further agree
that they shall discuss and agree upon the language of any public disclosure concerning this termination in advance. 
  

	
	 Very truly yours,

	
	CTI TECHNOLOGIES, INC.
	
	 /s/ James Bianco

	 James A. Bianco, M.D.
 President & Chief Executive Officer

 Acknowledged and Agreed: 
 CHUGAI PHARMACEUTICAL CO., LTD. 
  

			
	 By:
	 	 /s/ K. Nishimura

	 Name:
	 	Kimio Nishimura
	 Title:
	 	General Manager, Business Devloepment Dept.
	 Date:
	 	March 14, 2006Employment letter dated January 9, 2006 with Mark Varney, Ph.D.

 Exhibit 10.92 
  

			
	 

	 	Roger G. Stoll, Ph.D.
	 	Chairman, President, & Chief Executive Officer
	 	Cortex Pharmaceuticals, Inc.
	 	15231 Barranca Parkway
	 	Irvine, CA 92618
		 	Telephone: (949) 727-3157, ext. 101
		 	Facsimile: (949) 727-3657
		 	rstoll@cortexpharm.com

 December 22, 2005 
 Mark Varney, Ph.D. 
 [Address] 
 [City, State Zip Code]

 Dear Mark: 
 Subject to the approval of the Compensation
Committee of the Board of Directors, I am pleased to offer you employment with Cortex Pharmaceuticals, Inc. (“Cortex”) on the following terms and conditions: 
  

	1.	Your title will be Chief Scientific Officer and Chief Operating Officer, and you will report to the Chief Executive Officer. You will devote substantially all of your working time
to performing such duties and responsibilities as may be assigned to you from time to time commensurate with such position and refrain from any outside activities that might interfere with your duties or create a potential conflict of interest.

  

	2.	We anticipate that you will begin your service with Cortex as soon as practicable, but in no event later than January 30, 2006. 

  

	3.	You will receive a base salary of $300,000 per year minus appropriate withholding and payroll deductions, payable through Cortex’s regular payroll. In addition, you will be
reimbursed for customary employment related expenses. You will be entitled to receive an annual bonus of up to 30% of your base salary based on achievement of annual goals agreed upon between yourself and the CEO of Cortex. The payout will be
reviewed by and at the discretion of the Compensation Committee of the Board of Directors. 

  

	4.	You will receive the same package of benefits that Cortex currently provides to executives of a similar level to you. All of your benefits will be subject to the terms and
conditions of the various benefit plans and policies in effect and any changes to such plans and policies. 

  

	5.	Cortex will grant you a stock option (the “Option”) to purchase up to 750,000 shares of Common Stock with an exercise price equal to the fair market value on the first day
of your employment, determined in accordance with Cortex’s 

 Amended and Restated 1996 Stock Incentive Plan (the “Plan”). The right to purchase the shares
subject to the Option will vest in accordance with the following: 100,000 on your date of employment; 100,000 vesting after one year from your date of employment and 550,000 vesting in three annual installments of 33 1/3% each year from your date of
employment. To the extent permissible, the Option will be granted under, and will be subject to, the terms and conditions of the Plan, a copy of which will be delivered to you. 
 There are significant personal tax issues with the acceptance and exercise of the Option and you are advised to seek tax advice from a qualified tax
professional before accepting. 
 You will be an “executive officer” of Cortex under applicable securities laws and any
transactions in Cortex stock will be restricted by such laws and by Cortex’s internal policies with respect to stock transactions. Additionally after one year of employment, a decision will be made as to your nomination to the Cortex Board of
Directors by the Governance and Nominating Committee of the Board of Directors of Cortex. 
  

	6.	Cortex will assist in your relocation to Southern California by payment, or reimbursement on receipt of appropriate documentation, to you of the following: 

 

	 	•	 	Mortgage assistance program that will provide an interest subsidy over five (5) years in the form of monthly payment, whereby Company will pay 6% of the principal amount of a
mortgage (not to exceed $1,200,000) on your primary residence in Southern California interest during the first year of your employment, 5% during the second year, 4% during the third year, 3% during the fourth year, and 2% during the fifth year.
Such payments will terminate on any termination of your employment with Cortex. These payments will also be subject to an income tax gross up factor of 1.6. For example, during the first year you will receive payments of $72,000 but the company will
provide for an additional $43,200 of payments for tax purposes to be paid to the IRS by the company. This should reduce the tax burden of this additional income to you. 

  

	 	•	 	$25,000 bonus on commencement of employment. Should you leave the employment of the company within one year or less, you agree to reimburse Cortex for this hiring bonus.

  

	 	•	 	Temporary housing for a period of up to six months. This will include a completely furnished, two master bedroom, two full bathroom apartment at Promontory Point in Newport Beach.

  

	 	•	 	Reimbursement of costs of moving household furnishing, automobiles and other personal property from Massachusetts to the Orange County area in California. 

	 	•	 	Payment of $15,000 to cover miscellaneous expenses such as new draperies, etc. for your new residence in Southern California. 

  

	 	•	 	Reimbursement of normal and customary closing fees associated with the sale of your primary residence in Massachusetts. 

  

	 	•	 	Reimbursement of reasonable and customary real estate commissions for sale of your residence in Massachusetts, not to exceed 6%. 

  

	 	•	 	Reimbursement of normal and customary closing fees associated with the purchase of a primary residence in Southern California. 

  

	 	•	 	Allowance for travel to Massachusetts twice per month. This allowance will include efforts to schedule business meetings on the East Coast to augment such travel to Massachusetts.

  

	7.	In the event of termination of your employment by the Company without cause in connection with, or within six (6) months following a “Change In Control” (as defined
in the Plan) you shall be entitled to termination pay equal to twelve months of your Base Salary. The payments shall be in lieu of all damages and other compensation to which you may be entitled, under any employment agreement or otherwise, by
reason of termination of your employment and shall also be in lieu of further salary payments to you for periods subsequent to the termination of your employment. The payment shall not be considered compensation for any benefit calculation or other
benefit plan maintained by the Company. The payments will be paid to you in a lump sum, net of all applicable withholding taxes, within 30 days after your date of termination. You will also receive payment for all unpaid, paid time off days that you
have accrued through the date of your termination. In the event you receive payment, you shall also be entitled to continue to participate in the Company’s employee benefit program, including medical, dental, and prescription coverage for a
period of twelve (12) months, to the extent permitted by the Company’s insurance provider. The related premiums for such benefits will be paid by the Company. Upon a Change of Control, all stock options then held by you shall vest
concurrently with such Change of Control. 

  

	8.	Cortex is an at-will employer, and your employment will not be for any specific term. You are free to resign, and Cortex is free to terminate your employment at any time, with or
without cause. 

  

	9.	This offer of employment is conditioned upon your completion to Cortex’s satisfaction of the following documents/requirements. Please read them carefully and contact me at
(949) 727-3157 if you need further clarification on any of the points discussed throughout the remainder of this letter. 

  

	 	(a)	Employment Application. 

	 	(b)	Employee Proprietary Information and Invention Assignment Agreement. 

  

	 	(c)	Employment Eligibility Verification (Form I-9): Documenting your eligibility to work in the United States as required by U.S. Immigration Law. 

 We are looking forward to your joining our company and providing the leadership necessary to allow for the optimal development of our AMPAKINE®
technology. I hope that we have provided you with the resources necessary to make your relocation to Southern California possible. I look forward to working with you and your participation with our management team at Cortex. 
 To confirm that you agree to the terms stated in this letter, please sign and date the enclosed copy of this letter and return it to me no later than January 3,
2006. 
 Very truly yours, 
  

	
	/s/ Roger G. Stoll
	
	Roger G. Stoll, Ph.D.
	Chairman, President, and Chief Executive Officer

 I agree to the terms stated in this letter. 
 Dated: 9 January, 2006 
  

	
	 /s/ Mark A. Varney

	Mark Varney, Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]